InvestorsHub Logo
Followers 276
Posts 32701
Boards Moderated 0
Alias Born 11/14/2013

Re: ou71764 post# 3131

Tuesday, 12/31/2013 11:31:30 AM

Tuesday, December 31, 2013 11:31:30 AM

Post# of 700553
Based upon preclinical maurine studies and at least one small human trial for DCVAX-Direct, I do not believe PD-L1 presents a significant hurdle for a far more potently staged dendritic cell injected directly into the tumor on the heels of chemo/radiation.

I do not know how DCVAX-L will fare against PD-L1 subgroups, but I suspect DCVAX-L will comfortably meet its primary endpoint and be approved as S.O.C in addition to ( but not subordinate to) chemo and radiation.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News